Top 20 by rev­enue: New analy­sis high­lights huge im­pact of tax re­form on many — but not all — of the top phar­ma gi­ants

Whether it was a new, kinder US tax pol­i­cy, a big — of­ten ag­ing — fran­chise drug or a se­ries of M&A deals, 2018 was a good if not great year for many of the top 20 phar­ma com­pa­nies in the world.

But not all.

Glob­al­Da­ta crunched the num­bers for every­one and came up with the chart be­low, out­lin­ing the win­ners and losers in the multi­na­tion­al game.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER